Management of patients with lower-risk myelodysplastic syndromes

Myelodysplastic syndromes (MDS) are a heterogeneous group of hematopoietic stem cell disorders characterized by ineffective hematopoiesis with abnormal blood cell development (dysplasia) leading to cytopenias and an increased risk for progression to acute myeloid leukemia (AML). Patients with MDS ca...

Descripción completa

Detalles Bibliográficos
Autores principales: Brunner, Andrew M., Leitch, Heather A., van de Loosdrecht, Arjan A., Bonadies, Nicolas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9751093/
https://www.ncbi.nlm.nih.gov/pubmed/36517487
http://dx.doi.org/10.1038/s41408-022-00765-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9751093/
https://www.ncbi.nlm.nih.gov/pubmed/36517487
http://dx.doi.org/10.1038/s41408-022-00765-8

Ejemplares similares